Reforms at the FDA Level

In response to internal FDA reforms, Molly Burich, MS; Amanda Forys, MSPH; Ha Kung Wong, JD; and Angus Worthing, MD, FACR, FACP, share their expectations concerning review and approval timelines for biosimilar products that are safe, effective, and priced competitively within the market.
November 14, 2017
View Text Version

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.